← Issue №20/ week of Nov 15, 2026/ the whole section, in full

Esophagus/Reflux, in full.

All 4 Esophagus/Reflux papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 4, in full

most clinically useful first
Esophagus/Reflux meta analysis · n=12,076 · Nov 13, 2026 · Clin Transl Gastro · IF 3.4

Prevalence of Gastroesophageal Reflux Disease in Adult Patients with Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis.

New evidencemeta-analysisepidemiologyGERD
Clinical takeawayKeep GERD in mind in adults with obstructive sleep apnea, especially with higher BMI, higher ESS scores or female sex; the authors advise caution, as heterogeneity was high and the risk factors rest on a limited number of studies.
What it foundThe pooled prevalence of GERD in OSA patients is 34% (95% CI: 25-44), with nGER prevalence at 43% (95% CI: 26-62).
ContextThis meta-analysis confirms a high co-prevalence of GERD and OSA, refining prior evidence by identifying specific risk factors and diagnostic methods (24-hour pH monitoring) that yield the highest prevalence estimates. However, pooled estimates must be interpreted with caution due to high statistical heterogeneity.
Emergingsuggested applicable standard· American College of Gastroenterology (ACG), ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ), Am J Gastroenterol 2022;117(1):27-56

… Where GERD is suspected but unclear and endoscopy shows no objective evidence, perform reflux monitoring OFF therapy to establish the diagnosis (strong, low); conversely, do NOT perform off-therapy reflux monitoring solely as a diagnostic test in patients already known to have LA grade C or D esophagitis or long-segment Barrett's, because the diagnosis is already established (strong, low). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

In patients with classic GERD symptoms (heartburn, regurgitation) and no alarm symptoms, give an 8-week trial of empiric PPI ONCE DAILY before a meal (strong, moderate evidence); administer PPI 30-60 minutes before a meal rather than at bedtime (strong, moderate). Endoscopy is the FIRST test in patients presenting with dysphagia or other alarm symptoms, the guideline names weight loss and GI bleeding, and also in patients with multiple risk factors for Barrett's esophagus (strong, low). If classic symptoms respond to the 8-week trial, attempt to discontinue the PPI (conditional, low); for patients without erosive esophagitis or Barrett's whose symptoms resolved, an attempt at discontinuation should be made; patients requiring maintenance should take the lowest effective dose. If symptoms do not respond adequately to the 8-week trial, or return on discontinuation, perform diagnostic endoscopy, ideally after PPIs are stopped for 2-4 weeks (strong, low). Where GERD is suspected but unclear and endoscopy shows no objective evidence, perform reflux monitoring OFF therapy to establish the diagnosis (strong, low); conversely, do NOT perform off-therapy reflux monitoring solely as a diagnostic test in patients already known to have LA grade C or D esophagitis or long-segment Barrett's, because the diagnosis is already established (strong, low). In refractory GERD, optimize PPI therapy first (strong, moderate); then pH monitoring OFF PPIs if GERD was not previously established by pH study, long-segment Barrett's, or LA grade C/D esophagitis, versus impedance-pH ON PPIs where GERD is already established but symptoms persist on twice-daily PPI (both conditional, low). Before antireflux surgery or endoscopic therapy, HRM is recommended to rule out achalasia and absent contractility, with provocative testing (e.g., multiple rapid swallows) to identify contractile reserve in ineffective esophageal motility; on-therapy reflux monitoring is suggested before intervention in patients with prior objective GERD findings who remain symptomatic. Antireflux surgery by an experienced surgeon is an option for patients with OBJECTIVE evidence of GERD, with severe esophagitis (LA C/D), large hiatal hernia, or persistent troublesome symptoms benefiting most; TIF is suggested only for troublesome regurgitation or heartburn in patients who do not wish to undergo antireflux surgery and who are WITHOUT severe esophagitis (LA C/D) or hiatal hernia >2 cm. For extraesophageal symptoms WITHOUT typical GERD symptoms, perform reflux testing BEFORE starting PPI therapy (strong, moderate); with concomitant typical symptoms, consider twice-daily PPI for 8-12 weeks before further testing (conditional, low). Lifestyle: weight loss in overweight/obese patients (strong, moderate); avoid meals within 2-3 hours of bedtime, avoid tobacco, avoid trigger foods, and elevate the head of the bed for nighttime symptoms (all conditional, low).

American College of Gastroenterology (ACG), ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ), Am J Gastroenterol 2022;117(1):27-56 · reviewed 2026-07-23 ↗
Khampitak T … Sawanyawisuth K · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
Esophagus/Reflux systematic review · Nov 12, 2026 · Am J Gastro · IF 9.8

The role of high-resolution manometry in the assessment of altered foregut anatomy: scoping review and interpretation recommendations.

New evidenceesophageal motilitysystematic reviewguideline
Clinical takeawayIntegrate anatomic information and focus on clinically actionable findings, particularly obstructive states, when interpreting HRM in patients with altered foregut anatomy or post-surgical states, such as post-fundoplication or bariatric surgery.
What it foundHRM identifies post-fundoplication outflow obstruction (PFOO) and junctional disruption, and bariatric surgery alters esophagogastric junction anatomy, resulting in hypocontractile or obstructive manometric patterns. Specific HRM metrics include elevated IRP and obstruction on provocative maneuvers for unsuccessfully treated achalasia.
ContextRefines current practice by addressing HRM interpretation in altered foregut anatomy, which the Chicago Classification does not cover, emphasizing the need for anatomic integration and clinically actionable findings.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Barchi A … Bredenoord AJ · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Esophagus/Reflux rct · n=13 · Nov 10, 2026 · Endoscopy · IF 11.8

Phase I Trial of Liquid Nitrogen Spray Cryotherapy concurrent with neoadjuvant chemoradiation for Locally Advanced Esophageal Cancer: Dose Escalation and Long-Term Overall Survival.

New evidenceesophageal cancerbiomarkerbasic science
Clinical takeawayThis phase 1 trial supports further investigation of LNSC concurrent with CRT in phase 2 trials.
What it foundLNSC concurrent with CRT achieved 70% complete clinical response and 40% overall survival at 36 months, with no grade 2 or 3 adverse events.
ContextThis is the first study to evaluate LNSC concurrent with CRT in patients with locally advanced esophageal cancer, showing feasibility and potential efficacy.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Shah T … Patel B · Endoscopy · IF 11.8 · PubMed ↗Permalink
Esophagus/Reflux retrospective · n=184 · Nov 12, 2026 · Clin Transl Gastro · IF 3.4

Esophageal Squamous Papillomas: Human Papillomavirus Association and Natural History.

New evidenceesophageal cancerdysphagiabiomarker
Clinical takeawayDo not routinely test for HPV in typical, non-dysplastic ESPs, as HPV is unlikely to play a significant role in their pathogenesis.
What it foundNo transcriptionally active HPV detected in ESPs (0/177; 95% CI, 0-2.1%), and no dysplasia or malignant transformation observed over a median 24-month follow-up.
ContextChallenges prior conflicting evidence on HPV association with ESPs, supporting the benign natural history of these lesions in typical, non-dysplastic cases.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Haroon W … Garber A · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
← Back to issue №20 Every section of this issue is one click away, at the top of this page. Follow Esophagus/Reflux by RSS